Sandoz has begun a Phase III clinical trial with its biosimilar version of AbbVie‘s Humira (adalimumab). This is Sandoz’s eighth Phase III trial initiation for a biosimilar and its sixth biosimilar to reach that stage. Sandoz is also conducting Phase III trials of biosimilars for Amgen’s Enbrel and Roche/Genentech’s Rituxan/MabThera. The study is intended to demonstrate equivalent efficacy, similarity, and immunogenicity of Sandoz’s product versus Humira in patient...